{"id":{"repo_id":"brazil-ufpb","oai_identifier":"oai:repositorio.ufpb.br:123456789/607"},"canonical_url":"https://search.dev.ndltd.org/etd/brazil-ufpb/oai:repositorio.ufpb.br:123456789/607","repository":{"repo_id":"brazil-ufpb","name":"Brazil UFPB","base_url":"https://repositorio.ufpb.br/oai/request"},"display":{"title":"Evolução da leucemia mielóide crônica frente à terapia com inibidores de tirosina cinase.","abstract":"The Chronic Myeloid Leukemia (CML ) is a myeloproliferative disease by developing skilled clone of hematopoietic cells carrying Philadelfia chromoso me ( Ph ) , deriving the respective translocation between the long arms of chromosomes 9 and 22 , t( 9:22) (q34;11 ). As a result of this molecular translocatio n, there yielding a fusion BCR - ABL gene, which encodes an abnormal protein constitutively a ctive . The d evelopm ent of tyrosine kinase (ITK) BCR - ABL , princi pled for more than a decade ago , has revo lutionized the treatment of CML . The sources used for the development of scientific origin were working in the a reas of Oncology and Hematology . The information was tak en from bibliographic databases , searched from J anuary 2013 until February 2014 , investigated in the Ministry of Hea lth website of Medline/PubMed, Scielo, Scirus , and Science Direct and Ordinance Nº 1219 data, November 4 201 3/MS . The treatment of leukemia is focused on expanding the possibilities for healing and improving qu ality of life of these patients . The oral chemotherapy is a new tool for cancer treatment , and has been proven effective and is becoming more common be cause it is simple, economical, non - i nvasive and less toxic . Is also possible that the treatment is performed in the patient's home . Among the tr eatments available for leukemia , oral chemothera py is through preventive agents , as is the case of imatin ib (Glivec ® ), Dasatinib (Sprycel ® ) and Nilotinib (Tasigna ® ) that are used by chemotherapy patients with Chronic Myeloid Leukemia (LMC) . This study aims to review information about CML and treatment progress against ITK","abstract_html":"The Chronic Myeloid Leukemia (CML ) is a myeloproliferative disease by developing skilled clone of hematopoietic cells carrying Philadelfia chromoso me ( Ph ) , deriving the respective translocation between the long arms of chromosomes 9 and 22 , t( 9:22) (q34;11 ). As a result of this molecular translocatio n, there yielding a fusion BCR - ABL gene, which encodes an abnormal protein constitutively a ctive . The d evelopm ent of tyrosine kinase (ITK) BCR - ABL , princi pled for more than a decade ago , has revo lutionized the treatment of CML . The sources used for the development of scientific origin were working in the a reas of Oncology and Hematology . The information was tak en from bibliographic databases , searched from J anuary 2013 until February 2014 , investigated in the Ministry of Hea lth website of Medline/PubMed, Scielo, Scirus , and Science Direct and Ordinance Nº 1219 data, November 4 201 3/MS . The treatment of leukemia is focused on expanding the possibilities for healing and improving qu ality of life of these patients . The oral chemotherapy is a new tool for cancer treatment , and has been proven effective and is becoming more common be cause it is simple, economical, non - i nvasive and less toxic . Is also possible that the treatment is performed in the patient's home . Among the tr eatments available for leukemia , oral chemothera py is through preventive agents , as is the case of imatin ib (Glivec ® ), Dasatinib (Sprycel ® ) and Nilotinib (Tasigna ® ) that are used by chemotherapy patients with Chronic Myeloid Leukemia (LMC) . This study aims to review information about CML and treatment progress against ITK","abstract_has_math":false,"creators":["Medeiros, Leanio Eudes dos Santos"],"institution":"Universidade Federal da Paraíba","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014-07-22","date_published":"2014-07-22","updated_at":"2026-07-24T01:18:00Z","subjects":["Leucemia mieloíde crônica","Terapia com inibidores","Tirosina cinase"],"languages":["pt"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://repositorio.ufpb.br/jspui/handle/123456789/607","outbound_label":"Repository record","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Medeiros, Leanio Eudes dos Santos"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-07-22T13:52:59Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-07-22T13:52:59Z"]},{"key":"dc:date.issued","label":"Date","values":["2014-07-22"]},{"key":"dc:publisher","label":"Institution","values":["Universidade Federal da Paraíba"]},{"key":"dc:type","label":"Dc Type","values":["TCC"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Leucemia mieloíde crônica","Terapia com inibidores","Tirosina cinase"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["pt"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://repositorio.ufpb.br/jspui/handle/123456789/607"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The Chronic Myeloid Leukemia (CML ) is a myeloproliferative disease by developing skilled clone of hematopoietic cells carrying Philadelfia chromoso me ( Ph ) , deriving the respective translocation between the long arms of chromosomes 9 and 22 , t( 9:22) (q34;11 ). As a result of this molecular translocatio n, there yielding a fusion BCR - ABL gene, which encodes an abnormal protein constitutively a ctive . The d evelopm ent of tyrosine kinase (ITK) BCR - ABL , princi pled for more than a decade ago , has revo lutionized the treatment of CML . The sources used for the development of scientific origin were working in the a reas of Oncology and Hematology . The information was tak en from bibliographic databases , searched from J anuary 2013 until February 2014 , investigated in the Ministry of Hea lth website of Medline/PubMed, Scielo, Scirus , and Science Direct and Ordinance Nº 1219 data, November 4 201 3/MS . The treatment of leukemia is focused on expanding the possibilities for healing and improving qu ality of life of these patients . The oral chemotherapy is a new tool for cancer treatment , and has been proven effective and is becoming more common be cause it is simple, economical, non - i nvasive and less toxic . Is also possible that the treatment is performed in the patient's home . Among the tr eatments available for leukemia , oral chemothera py is through preventive agents , as is the case of imatin ib (Glivec ® ), Dasatinib (Sprycel ® ) and Nilotinib (Tasigna ® ) that are used by chemotherapy patients with Chronic Myeloid Leukemia (LMC) . This study aims to review information about CML and treatment progress against ITK"]},{"key":"dc:title","label":"Title","values":["Evolução da leucemia mielóide crônica frente à terapia com inibidores de tirosina cinase."]}]}],"canonical_facts":{"dc:creator":["Medeiros, Leanio Eudes dos Santos"],"dc:date.accessioned":["2014-07-22T13:52:59Z"],"dc:date.available":["2014-07-22T13:52:59Z"],"dc:date.issued":["2014-07-22"],"dc:description.abstract":["The Chronic Myeloid Leukemia (CML ) is a myeloproliferative disease by developing skilled clone of hematopoietic cells carrying Philadelfia chromoso me ( Ph ) , deriving the respective translocation between the long arms of chromosomes 9 and 22 , t( 9:22) (q34;11 ). As a result of this molecular translocatio n, there yielding a fusion BCR - ABL gene, which encodes an abnormal protein constitutively a ctive . The d evelopm ent of tyrosine kinase (ITK) BCR - ABL , princi pled for more than a decade ago , has revo lutionized the treatment of CML . The sources used for the development of scientific origin were working in the a reas of Oncology and Hematology . The information was tak en from bibliographic databases , searched from J anuary 2013 until February 2014 , investigated in the Ministry of Hea lth website of Medline/PubMed, Scielo, Scirus , and Science Direct and Ordinance Nº 1219 data, November 4 201 3/MS . The treatment of leukemia is focused on expanding the possibilities for healing and improving qu ality of life of these patients . The oral chemotherapy is a new tool for cancer treatment , and has been proven effective and is becoming more common be cause it is simple, economical, non - i nvasive and less toxic . Is also possible that the treatment is performed in the patient's home . Among the tr eatments available for leukemia , oral chemothera py is through preventive agents , as is the case of imatin ib (Glivec ® ), Dasatinib (Sprycel ® ) and Nilotinib (Tasigna ® ) that are used by chemotherapy patients with Chronic Myeloid Leukemia (LMC) . This study aims to review information about CML and treatment progress against ITK"],"dc:identifier.uri":["https://repositorio.ufpb.br/jspui/handle/123456789/607"],"dc:language.iso":["pt"],"dc:publisher":["Universidade Federal da Paraíba"],"dc:subject":["Leucemia mieloíde crônica","Terapia com inibidores","Tirosina cinase"],"dc:title":["Evolução da leucemia mielóide crônica frente à terapia com inibidores de tirosina cinase."],"dc:type":["TCC"]},"updated_at":"2026-07-24T01:18:00Z"}